Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04088851

"Hepatic Substrate Flux Rates in Type 2 Diabetes"

Investigation of the effects of redox shuttle inhibition by metformin on gluconeogenic flux rates of lactate and glycerol in humans with type 2 diabetes

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

German Diabetes Center

Düsseldorf, North Rhine-Westphalia, 40225, Germany

About this study

Type 2 diabetes (T2D) is characterized by insulin resistance and relative insulin deficiency leading to hyperglycemia. Enhanced endogenous glucose production during fasting is a key feature of hepatic insulin resistance and a major contributor to deterioration of glycemia. Metformin reduces fasting gluconeogenesis (GNG); the underlying mechanisms are still not fully understood, but involve the inhibition of complexes of the electron transport chain and thus the redox shuttle.

The investigators have previously provided evidence for abnormal hepatic ATP synthesis and mitochondrial efficiency in T2D, but it remains unknown, how and which substrate fluxes account for excessive GNG in T2D. For this reason, this proposal aims at investigating hepatic glucose and energy fluxes in T2D with focus on gluconeogenic contribution of lactate and glycerol to hepatic mitochondrial substrate flux, mitochondrial ATP synthase flux and the activity of the redox shuttle, also after metformin intake, by using a novel combination of positional isotopomer nuclear magnetic resonance (NMR) analysis (PINTA) with multinuclei magnetic resonance spectroscopy (MRS).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • type 2 diabetes (duration <7 years),
  • age (18-75 years)
  • BMI <40 kg/m2
  • HbA1c 6-15%

Exclusion criteria

  • uncontrolled hyperglycaemia (>340 mg/dl)
  • diabetes types other than type 2 diabetes (ADA criteria)
  • thiazolidinedione use during the preceding 6 months
  • clinically relevant angiopathy, restrictive or obstructive lung diseases
  • other acute or chronic diseases including wounds and the use of pharmacological agents known to affect insulin sensitivity, lipid metabolism or immunological function.

Treatment and study plan

On Metformin

Drug

Oral intake of Metformin (1 g / day) for 2 weeks

Off Metformin

Drug

No oral intake of Metformin (1 g / day) for 2 weeks

Primary outcomes

  1. Hepatic gluconeogenic flux (U-13C-lactate tracer) (mg/min)

    Time frame: 2 weeks

    Hepatic gluconeogenic flux rates from lactate [mg/min] in humans with T2D w/wo metformin treatment will be measured by specific tracer metabolism and turnover of the substrates.

  2. Hepatic gluconeogenic flux (glycerol tracer) (mg/min)

    Time frame: 2 weeks

    Hepatic gluconeogenic flux rates from glycerol [mg/min] in humans with T2D w/wo metformin treatment will be measured by specific tracer metabolism and turnover of the substrates.

Secondary outcomes

  1. Endogenous glucose production (mg/min/kg BW)

    Time frame: 2 weeks

    Endogenous glucose production (mg/min/kg BW) in humans with T2D w/wo metformin treatment will be measured by specific tracer metabolism and turnover of the substrates.

  2. Hepatic mitochondrial oxidative flux (mg/min)

    Time frame: 2 weeks

    Hepatic mitochondrial oxidative flux (mg/min) in humans with T2D w/wo metformin treatment will be measured by specific tracer metabolism and turnover of the substrates.

  3. Hepatic gammaATP (mmol/L)

    Time frame: 2 weeks

    Hepatic energy [ATP mmol/l] content will be assessed in people with T2D with and without metformin treatment by employing specific 31P- magnetic resonance spectroscopy.

  4. Hepatic lipid content (%)

    Time frame: 2 weeks

    Hepatic fat [%] content will be assessed in people with T2D with and without metformin treatment by employing specific 1H- magnetic resonance spectroscopy.

Sponsors and collaborators

Lead sponsor

German Diabetes Center

Other

Collaborators

  • Yale University

Registry information

Official study title

"Non-invasive Measurement of Hepatic Substrate Flux Rates in People with Diabetes Mellitus Type 2"

Acronym: IMPACT

Important dates

Study start
2019
Primary completion
2025
Study completion
2025
First posted
Sep 13, 2019
Registry last updated
Jan 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.